Lonza announced that it has entered into a long-term commercial supply agreement with Vertex Pharmaceuticals to manufacture Casgevy (exagamglogene autotemcel), the first clustered regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9)-gene-edited cell therapy for treating sickle cell disease (SCD) and β thalassemia. Lonza plans to manufacture Casgevy at its cell therapy manufacturing facilities in Geleen, the Netherlands, with plans to expand to its Portsmouth, NH manufacturing facility in the United States. Source: Biopharm International 24/9/24